ANEB Stock Overview
A clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Anebulo Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.46 |
| 52 Week High | US$3.30 |
| 52 Week Low | US$1.25 |
| Beta | -1.01 |
| 11 Month Change | -20.22% |
| 3 Month Change | -24.94% |
| 1 Year Change | -34.82% |
| 33 Year Change | -76.71% |
| 5 Year Change | n/a |
| Change since IPO | -79.44% |
Recent News & Updates
Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation
Jun 22
Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?
Feb 18Recent updates
Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation
Jun 22Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?
Feb 18Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?
Jul 03Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth
Mar 07We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth
Nov 19Anebulo Pharmaceuticals to launch private investment in public equity financing
Sep 26Anebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03
Sep 09Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation
Jun 28Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth
Mar 15Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation
Nov 04Anebulo Pharmaceuticals reports FQ3 results
Jun 21Shareholder Returns
| ANEB | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -8.1% | 1.6% | 2.2% |
| 1Y | -34.8% | 9.9% | 31.6% |
Return vs Industry: ANEB underperformed the US Pharmaceuticals industry which returned 10% over the past year.
Return vs Market: ANEB underperformed the US Market which returned 31.7% over the past year.
Price Volatility
| ANEB volatility | |
|---|---|
| ANEB Average Weekly Movement | 20.4% |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: ANEB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ANEB's weekly volatility has increased from 15% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 3 | Richie Cunningham | www.anebulo.com |
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing treatments for unintentional cannabis poisoning, acute cannabinoid intoxication, and acute cannabis-induced conditions in the United States. Its lead product candidate is the selonabant, a small molecule antagonist of cannabinoid binding receptor type-1, which is in a phase II clinical trial to address the unmet medical need for a specific antidote for cannabis toxicity. The company was incorporated in 2020 and is based in Lakeway, Texas.
Anebulo Pharmaceuticals, Inc. Fundamentals Summary
| ANEB fundamental statistics | |
|---|---|
| Market cap | US$37.86m |
| Earnings (TTM) | -US$7.92m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.8x
P/E RatioIs ANEB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ANEB income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$7.92m |
| Earnings | -US$7.92m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.31 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ANEB perform over the long term?
See historical performance and comparison